For the Inventor, By the Inventor

Enter assignee name

Rockville, MD, United States of America

Reveragen Biopharma, Inc.

USPTO Granted Patents = 15

EPO Patents = 3

Forward Citations = 66

Loading Chart...

Loading Chart...

7 inventors (with patents filed for the assignee):

John Michael McCall (13 out of 54 patents)

Eric Hoffman (12 out of 17 patents)

Kanneboyina Nagaraju (10 out of 12 patents)

4. Jesse Damsker (6 out of 8 patents)

5. Nagaraju (Raju) Kanneboyina (1 out of 1 patent)

6. Alyson Fiorillo (1 out of 3 patents)

7. John Mccall (1 out of 3 patents)

8. John M Mccall (0 patent)

9. Nagaraju Kanneboyina (0 patent)

15 patents: Sort by Forward Citations

1. 12201639 - Aqueous oral pharmaceutical suspension compositions (2025-01-21),

2. 11833159 - Non-hormonal steroid modulators of NF-kB for treatment of disease (2023-12-05),

3. 11690853 - Non-hormonal steroid modulators of NF-κβ for treatment of disease (2023-07-04),

4. 11471471 - Aqueous oral pharmaceutical suspension compositions (2022-10-18),

5. 11382922 - Aqueous oral pharmaceutical suspension compositions (2022-07-12),

6. 10857161 - Non-hormonal steroid modulators of NF-kB for treatment of disease (2020-12-08),

7. 10799514 - Non-hormonal steroid modulators of NF-kappa beta for treatment of disease (2020-10-13),

8. 10464967 - Non-hormonal steroid modulators of NF-κβ for treatment of disease (2019-11-05),

9. 10206933 - Non-hormonal steroid modulators of NF-kB for treatment of disease (2019-02-19),

10. 10000525 - Non-hormonal steroid modulators of NF-κB for treatment of disease (2018-06-19),

11. 9649320 - Non-hormonal steroid modulators of NF-κB for treatment of disease (2017-05-16),

12. 9637738 - Methods and agents to increase therapeutic dystrophin expression in muscle (2017-05-02),

13. 9434758 - Non-hormonal steroid modulators of NF-κB for treatment of disease (2016-09-06),

14. 9198921 - Non-hormonal steroid modulators of NF-κB for treatment of disease (2015-12-01),

15. 8673887 - Non-hormonal steroid modulators of NF-kB for treatment of disease (2014-03-18),

ReveraGen BioPharma, Inc. is a pharmaceutical company focused on the development and commercialization of innovative therapeutics. With a primary focus on Duchenne muscular dystrophy (DMD), ReveraGen is dedicated to improving the lives of patients through the discovery of novel treatments. Leveraging cutting-edge research and scientific expertise, the company is committed to bringing transformative therapies to market.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Reveragen Biopharma, Inc.

15 Patents

#46 in Rockville, MD

#293 in Maryland

#21,011 in US

#39,801 in the World

Rockville, MD, United States of America

Reveragen Biopharma, Inc.

Forward Citations = 66

7 inventors:

John Michael McCall (13 out of 54 patents)

Eric Hoffman (12 out of 17 patents)

Kanneboyina Nagaraju (10 out of 12 patents)

4. Jesse Damsker (6 out of 8 patents)

5. Nagaraju (Raju) Kanneboyina (1 out of 1 patent)

Please report any incorrect information to [email protected]

Loading…